Kyverna to present phase 2 myasthenia gravis data at AANEM meeting
PositiveFinancial Markets

Kyverna will present new data from its phase 2 study on myasthenia gravis at the upcoming AANEM meeting, showcasing advancements in treatment options.
Editor’s Note: This presentation is significant as it highlights ongoing research and potential breakthroughs in treating myasthenia gravis, a condition that affects muscle strength and can severely impact patients' quality of life.
— Curated by the World Pulse Now AI Editorial System